VIDEO: Post-transplant consolidation with nivolumab, brentuximab shows promise in Hodgkin lymphoma
Consolidation with nivolumab and brentuximab vedotin after autologous hematopoietic cell transplantation showed promise in patients with high-risk Hodgkin lymphoma, according to a presentation at the ASH Annual Meeting and Exposition.
“I think this is appealing,” Ann S. LaCasce, MD, MSc, of Dana-Farber Cancer Institute, said in a video interview. “What is going to change moving forward is more and more patients are probably going to be exposed to brentuximab in the front-line setting and I think that’s going to impact significantly on how we think about subsequent consolidation or transplant options.”
Collapse
Herrera AF, et al. Abstract 472. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.